In total, for 2025, 2.18 million packages of emergency contraception drugs were sold on the Russian retail market, amounting to RUB 1.9 billion (at retail prices, including VAT). Compared to 2024, we are recording a significant drop in demand, with dynamics in packages recorded at -5.3%, while the growth rate in ruble terms remains in positive territory (+6.9%). Consumption rates for this drug category have been declining for the second consecutive year, although an absolute maximum in the physical sales volume of postcoital contraceptives was reached in 2024 at 2.3 million packages. In January 2026, negative trends in the segment continued. According to the database "Retail Audit of Drug Sales in Russia (total sell out)" from the analytical company RNC Pharma, pharmacies sold 197,100 packages of emergency contraceptives worth RUB 177.3 million in that month. The physical volume decreased by 1.4% compared to January 2025, while the monetary volume grew by 5.1%.

The regional consumption pattern for the analyzed products varies significantly. In terms of absolute sales volumes, Moscow and Moscow Oblast lead, together accounting for 16.2% of the total market's monetary volume in 2025. Third place is held by Krasnodar Krai with a 5.3% share. All three regions were characterized by negative consumption dynamics last year, with the most noticeable decline recorded in Krasnodar Krai (-11%). However, in terms of per capita consumption volumes of postcoital contraceptives, Moscow is not in the top tier; moreover, the region ranks only 32nd, with just 14.9 packages sold per 1,000 people in 2025. This is, incidentally, almost exactly in line with the national average of 14.5 packages per 1,000 people. The absolute leader for several consecutive years remains the Altai Republic, where an average of 24.3 packages per 1,000 people were purchased last year. Nevertheless, even here, the overall demand dynamic is in negative territory. Second place in per capita consumption is held by Krasnodar Krai (19.8 packages per 1,000 people). Among other major regions, the Republic of Tatarstan (19.1) and Moscow Oblast (18.2) can also be mentioned. Growth in per capita demand volumes for emergency contraception drugs was recorded in only five federal subjects of our country. The most notable dynamics were observed in Kursk Oblast and the Republic of Dagestan, although the latter is characterized by minimal consumption volumes in the category, at 5.5 packages per 1,000 people.

In terms of the competitive landscape, levonorgestrel drugs dominate the segment. The absolute leader is Gedeon Richter with its drugs Escapelle and Postinor, which together account for nearly 90.8% of the market's monetary volume. Another 9.1% of sales come from the drug Postiplania by Pharmasyntez. However, sales of products based on mifepristone at a 10 mg dosage have almost completely ceased. After the drug was added to the subject-quantitative control list, its production was halted, and remaining stocks are now being sold off. For instance, during the entire 2025, total sales of the drug Genale from Izvarino Pharma amounted to just 3,400 packages.